Trial Profile
Gefitinib in Serbian lung cancer patients with EGFR mutations
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Oct 2018
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
- 21 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.